MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

According to our recent payer coverage analysis for non-small cell lung cancer systemic therapy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer systemic therapy treatments shows that under the pharmacy benefit, about 46% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) on May 6, 2020, it was the first of seven approvals in non-small cell lung cancer (NSCLC) through May 29.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-reality-check-hemophilia.jpg
October 15

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/wordpress-featured-image-reality-check-diffuse-large-b-cell-lymphoma.jpg
October 8

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image_Pulse-Check_MS.jpg
October 1

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today